Core Viewpoint - Pfizer's shares are currently trading at approximately $25, reflecting a challenging performance over the past three years, raising questions about the company's investment potential moving forward [1] Group 1: Financial Performance - Pfizer's revenue and earnings have shown inconsistency in recent years, compounded by upcoming patent cliffs, notably for Eliquis, one of its top-selling drugs [3] - The company has been gradually securing new approvals that could positively impact its financial results through label expansions [3] Group 2: Strategic Moves - Pfizer has intensified its acquisition strategy, enhancing its product pipeline with a focus on cancer therapies and a promising weight loss candidate [4] - The company is expected to launch several new products that will strengthen its portfolio through the end of the decade [4] Group 3: Investment Considerations - Pfizer has established a deal with the Trump administration to avoid tariffs for three years, which could benefit its financial standing [8] - The company has a strong dividend history, increasing payouts by 51.3% over the past decade, with a current yield of 6.9% [8] - Pfizer's stock is trading at 8.5 times forward earnings, significantly lower than the healthcare sector average of 18.4, making it an attractive investment option [8]

Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists IBD Live Leaderboard SwingTrader MarketSurge IBD Digital MarketDiem The Wall Street Journal Barron's MarketWatch Dow Jones Smart Money Connect With Us On stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any speci ...

Core Insights - Encompass Health Corporation (EHC) is experiencing growth due to increasing patient volumes, expansion initiatives, and a strong financial position [1] Financial Performance - EHC has a Zacks Rank of 2 (Buy) and its stock has increased by 16.6% over the past year, outperforming the industry growth of 7.2% [2] - The Zacks Consensus Estimate for EHC's 2025 earnings is $5.30 per share, reflecting a year-over-year increase of 19.6%, with revenues expected to reach $5.9 billion, indicating a 10.4% growth [5] - The 2026 earnings estimate is $5.81 per share, showing a 9.6% increase from 2025 [5] - The consensus estimate for 2026 revenues is projected at $6.5 billion, representing an 8.8% growth from the 2025 estimate [6] - EHC's earnings have consistently surpassed estimates, with an average surprise of 12.47% over the last four quarters [8] Growth Drivers - EHC's revenue growth is primarily driven by an expanding patient base in its inpatient rehabilitation hospitals, with a reported 10.6% revenue increase in the first nine months of 2025 compared to the same period in the previous year [9] - The company plans to add 150-200 beds in both 2026 and 2027, supported by a robust financial foundation, including $48.7 million in cash and cash equivalents as of September 30, 2025, and $829.6 million in operating cash flows for the first nine months of 2025, a 14.6% year-over-year increase [12] Expansion Initiatives - EHC is actively launching new inpatient rehabilitation hospitals, either independently or in collaboration with healthcare partners, enhancing its service capacity and nationwide footprint [10] - As of now, EHC operates 173 hospitals across 39 states and Puerto Rico, with the latest addition being the Rehabilitation Hospital of Lake Worth, opened in December [11]

Core Viewpoint - Boeing had a strong performance in 2025, and hedge fund manager Dan Niles anticipates continued stock growth into 2026, labeling it a "top pick" for the year in a CNBC interview [1] Group 1 - Boeing's stock is expected to keep climbing, driven by positive market sentiment and strong financial results [1] - Dan Niles' endorsement highlights investor confidence in Boeing's future prospects [1]

In 2024, Coupang acquired the luxury fashion marketplace Farfetch in a bid to enter the high-end retail segment. Coupang rescued Farfetch from insolvency and is using it to build a strong luxury presence in Asia, but it's still navigating hurdles in reigniting sales growth and navigating the complex luxury e-commerce landscape. Coupang's primary international focus is Taiwan, where it is replicating its Korean logistics model.Coupang also has an equivalent version of Amazon Prime called the Rocket WOW subsc ...

Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. ©2025 Investor's Business Daily, LLC. All Rights Reserved. About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Check ...

Core Insights - Elon Musk's purchase of Tesla shares in September 2025 has resulted in significant paper gains as the stock price increased towards the end of the year [1] - The shares were acquired at an average price of approximately $395.94, totaling around $1 billion, marking one of Musk's largest personal investments in Tesla [1] - As of December 28, 2025, Tesla shares were trading at approximately $475.19, reflecting a 20% increase from the purchase price, with Musk's stake now valued at about $1.2 billion [2] Stock Performance Overview - Tesla shares experienced volatility in 2025, initially declining due to Musk's focus on government work and weakening global sales, but rebounded strongly in December [3][4] - The stock's recovery was significant, pushing returns on Musk's investment well above the interim lows experienced earlier in the year [3] Market Sentiment and Investor Confidence - Investor sentiment improved in April 2025 when Musk announced a reduction in his Washington role, alleviating concerns about leadership focus and leading to a rally in Tesla's stock [4] - Momentum strengthened in May following a tariff truce between the US and China, which positively impacted Tesla's supply chain and international demand [6] - Tesla's board proposed a substantial compensation package for Musk, further boosting investor confidence, coinciding with Musk's $1 billion stock purchase, signaling strong belief in the company's future [6]

Core Insights - U.S. stock owners experienced significant gains at the beginning of the year, indicating a strong performance in the domestic market [1] - Foreign stocks outperformed U.S. stocks, suggesting that international investments provided even better returns for investors [1] Summary by Category U.S. Stocks - Investors who held U.S. stocks at the start of the year made substantial profits, reflecting a positive trend in the domestic equity market [1] Foreign Stocks - The performance of foreign stocks surpassed that of U.S. stocks, highlighting the advantages of diversifying investments internationally [1]

Core Insights - Adobe (ADBE) reported Q4/2025 earnings on December 10, 2025, showing consistent growth, yet the stock price has only increased by 2.7% since the earnings date, indicating underperformance compared to the overall market this year [1] Financial Performance - The company demonstrated consistent growth in its earnings report for Q4/2025, although specific financial metrics were not detailed in the provided text [1] Market Performance - Adobe's stock has significantly underperformed the overall market throughout the year, suggesting potential concerns regarding investor sentiment or market positioning [1]